ESPE Abstracts (2018) 89 P-P3-201

ESPE2018 Poster Presentations GH & IGFs P3 (28 abstracts)

Effects on Near-adult Height and Safety of Recombinant Human Growth Hormone in Growth Hormone Deficiency and Turner Syndrome Patients: Results from the LG Growth Study

Jin-Ho Choi a , Sochung Chung b , Young-Jun Rhee c , Jae Hyun Kim d , Hyun-Wook Chae e , Jae-ho Yoo f , Young Ah Lee g & Il Tae Hwang h


aDepartment of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; bDepartment of Pediatrics, Konkuk University School of Medicine, Seoul, Republic of Korea; cDepartment of Pediatrics, Korea University College of Medicine, Ansan, Republic of Korea; dDepartment of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea; eDepartment of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea; fDepartment of Pediatrics, College of Medicine, Dong-A University, Busan, Republic of Korea; gDepartment of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea; hDepartment of Pediatrics, College of Medicine, Hallym University, Seoul, Republic of Korea

Objectives: This study was performed to evaluate effectiveness on near-adult height (NAH) and safety of recombinant human growth hormone (rhGH) (Eutropin® Inj., Eutropin®Plus Inj., Eutropin®AQ Inj., LG Chem, Ltd.) treatment in children with growth hormone deficiency (GHD) and Turner syndrome (TS).

Methods: The LG Growth Study (LGS) is a multicenter, long-term, observational study designed to evaluate the long-term effectiveness and safety of rhGH treatment (NCT01604395). The data on NAH (height at ≥18 years of age, or height velocity <2 cm/year at ≥16 years for boys or ≥15 years for girls) and safety of rhGH were analyzed.

Results: This study included 51 GHD patients and 57 TS patients. At the start of treatment, the mean age of the patients with GHD and TS was 12.2±3.0 and 10.8±3.2 years, respectively. Bone age (BA) of GHD and TS was 10.5±3.1 and 9.7±2.8 years, respectively. The median initial rhGH dose was 0.2 and 0.3 mg/kg per week, respectively. The mean baseline height SDS (HtSDS) for GHD and TS patients was −2.80±1.45 and −3.51±0.84, respectively. The midparental height (MPH) SDS was −1.09±0.88 and −0.56±0.83, and a difference between baseline HtSDS and MPH SDS was −1.97±1.32 (95% CI: −2.44 to −1.51) and −2.86±0.95 (95% CI: −3.17 to −2.55), respectively. The mean age at the measurement of NAH for GHD and TS patients was 18.4±2.6 and 17.6±1.6 years, respectively. Duration of treatment was 4.9±2.7 and 5.3±2.5 years, respectively. There was no change of dose during the treatment period. The mean HtSDS for GHD and TS patients was −1.29±1.62 and −2.36±0.92 at NAH, and a difference between NAH SDS and MPH SDS were −0.22±1.03 (95% CI: −0.56 to 0.11) and −1.72±0.80 (95% CI: −1.96 to −1.49), respectively. Adverse events (AEs) were reported in 20 GHD patients (39.2%) and 28 TS patients (49.1%). The most common AEs were upper respiratory tract infection (9.3%) and headache (7.4%). Serious adverse drug reactions Craniopharyngioma was recurred in two patients with GHD (3.9%) during rhGH treatment.

Conclusions: In this study, rhGH treatment increased the HtSDS and reduced the gap between HtSDS and MPH SDS at NAH in both patients with GHD and TS.

Article tools

My recent searches

No recent searches.